XFOR
X4 Pharmaceuticals Inc
2.80$
+1.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -15.0% | -23.8% | +87.7% | -15.4% | -17.8% | -11.2% | -19.1% | +55.5% | +77.6% | -6.9% | -6.4% | |
| – | -17.4% | -28.5% | +100.9% | -18.5% | -21.5% | -14.7% | -23.8% | +82.1% | +97.0% | -7.5% | -9.6% | |
| – | -24.6% | -39.2% | +143.4% | -33.8% | -42.8% | -27.7% | -2.6% | +77.5% | +211.7% | -0.1% | -10.1% | |
| – | -19.4% | -29.4% | +108.7% | -20.0% | -24.4% | -14.8% | -27.6% | +94.1% | +107.0% | -7.6% | -11.0% | |
| – | +43.0% | +24.9% | +21.7% | +25.6% | +59.4% | -31.3% | +58.9% | -13.9% | -64.3% | +94.2% | +83.9% | |
| – | – | – | – | +194.2% | +15.2% | +9.7% | +2.6% | +28.7% | +9.8% | +3.5% | +18.7% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | – | – | – | -1.8% | -1.8% | -1.9% | -1.9% | -1.9% | -2.0% | -2.0% | +44.6% | |
| – | -9.0% | +15.6% | +4.5% | +2.1% | +4.9% | -13.9% | -5.5% | +0.7% | +2.2% | -2.2% | -4.1% | |
| – | -10.1% | +3.0% | +22.8% | +1.2% | +12.4% | -21.3% | -11.5% | +2.7% | +9.6% | -7.7% | -18.5% | |
| – | -1.5% | +3.1% | +3.4% | +4.3% | +2.4% | +4.2% | +5.0% | -12.3% | -17.2% | -26.3% | -36.6% | |
| – | +10.0% | -0.1% | -10.6% | +7.4% | +0.5% | +28.9% | -30.6% | -34.5% | +12.7% | -10.9% | -22.5% | |
| – | +0.5% | +0.5% | +36.9% | +0.3% | +0.3% | +0.3% | +0.3% | +0.3% | +0.3% | +0.3% | +0.3% | |
| – | -24.4% | -98.0% | +9,016.9% | -36.9% | -62.9% | +3.6% | -82.7% | +1,451.7% | +202.3% | -9.6% | -7.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.9% | +0.6% | +0.4% | +0.0% | +1.0% | +1.5% | +7.9% | +483.7% | +155.5% | +14.2% | +0.0% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.